Sharon L Mckenna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5633000/publications.pdf

Version: 2024-02-01

46 papers	9,290 citations	304743 22 h-index	254184 43 g-index
49 all docs	49 docs citations	49 times ranked	21526 citing authors

#	Article	IF	Citations
1	All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism. Frontiers in Oncology, 2022, 12, 848517.	2.8	3
2	Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death and Differentiation, 2021, 28, 2465-2481.	11.2	30
3	Lysosomes in acute myeloid leukemia: potential therapeutic targets?. Leukemia, 2021, 35, 2759-2770.	7.2	18
4	Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.8	1
5	Allâ€trans retinoic acid (ATRA)â€induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). European Journal of Haematology, 2020, 104, 236-250.	2.2	21
6	Inhibition of UBE2L6 attenuates ISGylation and impedes ATRAâ€induced differentiation of leukemic cells. Molecular Oncology, 2020, 14, 1297-1309.	4.6	15
7	Assessing Autophagy in Archived Tissue or How to Capture Autophagic Flux from a Tissue Snapshot. Biology, 2020, 9, 59.	2.8	12
8	Lentiviral-Mediated shRNA Approaches: Applications in Cellular Differentiation and Autophagy. Methods in Molecular Biology, 2019, 2019, 33-49.	0.9	1
9	The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. Journal of Controlled Release, 2018, 286, 154-166.	9.9	19
10	Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. Molecular Pharmaceutics, 2017, 14, 940-952.	4.6	56
11	UBE2L6/UBCH8 and ISG15 attenuate autophagy in esophageal cancer cells. Oncotarget, 2017, 8, 23479-23491.	1.8	37
12	MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells. BMC Cancer, 2016, 16, 101.	2.6	53
13	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
14	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opinion on Therapeutic Targets, 2016, 20, 107-121.	3.4	16
15	Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo. PLoS ONE, 2015, 10, e0134676.	2.5	32
16	Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Experimental Hematology, 2015, 43, 781-793.e2.	0.4	49
17	LC3B globular structures correlate with survival in esophageal adenocarcinoma. BMC Cancer, 2015, 15, 582.	2.6	19
18	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. Biotechnology Advances, 2014, 32, 1396-1409.	11.7	38

#	Article	IF	Citations
19	Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Experimental Cell Research, 2014, 324, 1-12.	2.6	37
20	ATRA-Induced Activation of the Autophagy Regulator Tfeb Regulates Myeloid Differentiation in Acute Promyelocytic Leukemia. Blood, 2014, 124, 1057-1057.	1.4	0
21	Induction of autophagy by Imatinib sequesters Bcrâ€Abl in autophagosomes and downâ€regulates Bcrâ€Abl protein. American Journal of Hematology, 2013, 88, 455-462.	4.1	45
22	Pharmacological agents with inherent anti-autophagic activity improve the cytotoxicity of imatinib. Oncology Reports, 2013, 29, 2261-2268.	2.6	25
23	Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 950-963.	4.9	13
24	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
25	Autophagy As a Target for Differentiation Therapy in Acute Myeloid Leukemia.. Blood, 2012, 120, 2464-2464.	1.4	2
26	VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin. Cellular Oncology (Dordrecht), 2011, 34, 225-234.	4.4	6
27	Autophagy induction by Bcrâ€Ablâ€expressing cells facilitates their recovery from a targeted or nontargeted treatment. American Journal of Hematology, 2011, 86, 38-47.	4.1	43
28	Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy, 2011, 7, 509-524.	9.1	220
29	Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy, 2011, 7, 509-24.	9.1	156
30	VHLGenetic Alteration in CCRCC Does Not Determine De-Regulation of HIF, CAIX, hnRNP A2/B1 and Osteopontin. Analytical Cellular Pathology, 2010, 33, 121-132.	1.4	8
31	Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents. Molecular Cancer Therapeutics, 2010, 9, 1328-1338.	4.1	27
32	Role of theVHL(von Hippelâ€“Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochemical Society Transactions, 2008, 36, 472-478.	3.4	65
33	Î²â€Catenin transcriptional activity is inhibited downstream of nuclear localisation and is not influenced by IGF signalling in oesophageal cancer cells. International Journal of Cancer, 2007, 121, 1903-1909.	5.1	6
34	Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2â€“independent mechanism and inhibits calcium-dependent apoptotic signaling. Blood, 2006, 107, 4003-4010.	1.4	32
35	Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing Cells. Molecular Cancer Research, 2006, 4, 457-469.	3.4	83
36	Autocrine secretion of osteopontin results in degradation of IkappaB in Bcr-Abl-expressing cells. British Journal of Haematology, 2005, 128, 711-721.	2.5	18

#	Article	IF	Citations
37	A Novel Bcr-Abl Mediated Pro-Survival Pathway: Reduction of Releasable Calcium Levels in the Endoplasmic Reticulum Inhibits Calcium Dependent Apoptotic Signaling.. Blood, 2005, 106, 2621-2621.	1.4	0
38	Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. British Journal of Haematology, 2003, 123, 34-44.	2.5	35
39	Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway. Leukemia Research, 2001, 25, 801-811.	0.8	14
40	Inhibition of caspase activity delays apoptosis in a transfected NS/0 myeloma cell line. Biotechnology and Bioengineering, 2000, 67, 165-176.	3.3	21
41	Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis. Oncologist, 2000, 5, 405-415.	3.7	62
42	Inhibition of caspase activity delays apoptosis in a transfected NS/0 myeloma cell line. Biotechnology and Bioengineering, 2000, 67, 165-76.	3.3	5
43	Alterations of the retinoic acid receptor Î± (RARÎ±) gene in myeloid and lymphoid malignancies. British Journal of Haematology, 1999, 104, 738-741.	2.5	6
44	Molecular mechanisms of programmed cell death. Advances in Biochemical Engineering/Biotechnology, 1998, 62, 1-31.	1.1	5
45	Functional Aspects of Apoptosis in Hematopoiesis and Consequences of Failure. Advances in Cancer Research, 1997, 71, 121-164.	5.0	45
46	MULTIDRUG RESISTANCE IN LEUKAEMIA. British Journal of Haematology, 1997, 96, 659-674.	2.5	65